Partnerships

Sobi’s $1.5 billion acquisition of Arthrosi Therapeutics positions the company for long-term growth and strengthens its gout treatment portfolio.

A successful transition from clinical development to commercial launch in cell and gene therapy requires early, structured collaboration with health systems to address operational, financial, and workflow challenges that shape real-world patient access and therapy adoption.

Pharmaceutical collaborations expand as Flagship Pioneering expands its partnership with GSK, signing agreements with ProFound Therapeutics and Quotient Therapeutics, while Valo Health teams up with Merck KGaA to tackle disease challenges.

Abbott's acquisition of Exact Sciences enhances cancer diagnostics and expands access to innovative screening and treatment solutions for patients worldwide.

GSK's collaborations leverage cutting-edge technology and scientific expertise to advance and accelerate research.

Avadel Pharmaceuticals accepted Alkermes enhanced acquisition proposal for $2.3 billion, focusing on a key treatment's approval for added value.

Eli Lilly partners with ABL Bio to research innovative therapeutics and expand its portfolio in cancer and CNS diseases through advanced bispecific antibody technology.

The agreement brings Cidara’s potential flu vaccine under Merck’s umbrella.

Bristol Myers Squibb and Sarah Cannon Research Institute expanded their strategic collaboration, leveraging SCRI’s Accelero model to streamline operations, embed studies within community care settings, and extend cutting-edge oncology therapies to more diverse patient populations.

How the Metsera deal extends Pfizer’s 25-year blueprint for growth.

Eli Lilly is partnering with MeiraGTx to develop and commercialize ophthalmology gene therapies, and with SanegeneBio to advance RNAi-based treatments for metabolic diseases, with the agreements collectively valued at more than $1.6 billion in potential milestone payments.

Metsera finalizes a $10 billion merger with Pfizer after rejecting Novo Nordisk's bids amid legal concerns to ensure shareholder value and regulatory safety.

Boehringer Ingelheim and Merck focus on innovative biologic and oncology advancements, driving collaborative growth through new R&D funding, and development and commercialization agreements.

Pharmaceutical collaborations thrive as Manifold Bio, 4DMT, and Kaigene forge strategic partnerships to advance innovative therapies for neurological and autoimmune diseases.

Pfizer's lawsuits come after Novo Nordisk proposed an unsolicited acquisition proposal to Metsera.

Novo Nordisk proposes a $9 billion acquisition of Metsera, prompting responses from both Metsera and Pfizer amid ongoing merger discussions.

Eli Lilly and NVIDIA unveil a groundbreaking AI supercomputer, revolutionizing drug discovery and accelerating patient care through advanced technology.

The acquisition aims to enhance drug development capabilities and accelerate clinical research innovation.

Zepbound will be offered as part of the LillyDirect program and will be available to patients for pick-up in over 4600 Walmart Pharmacies nationwide.

Eli Lilly plans to acquire Adverum Biotechnologies for $3.56 per share, enhancing its portfolio in innovative genetic medicines for vision restoration.

The acquisition aims to enhance Alkermes' entry into the sleep medicine market and expanding its product portfolio.

The collaboration will focus on enhancing cancer therapies through next-gen immuno-oncology and ADC treatments for solid tumors.

Pharmaceutical companies enhance cancer and autoimmune disease treatments through strategic collaborations, advancing innovative therapies, and improving patient outcomes.

The biopharmaceutical sector sees major acquisitions, enhancing capabilities in RNA therapies and rare diseases, with key players like BioCryst and Bristol Myers Squibb leading the charge.

Algen Biotechnologies partners with AstraZeneca to enhance AI-driven drug discovery, targeting chronic inflammatory conditions for innovative therapeutic solutions.